Related Experiment Videos
Specific transplantation immunity in relation to Rous sarcoma virus tumorigenesis in mice
Abstract:
Tests for transplantation immunity and for the occurrence of virus-neutralizing serum antibodies were performed on mice, inoculated when newborn with the Schmidt-Ruppin strain of Rous sarcoma virus (RSV-SR). Mice developing no palpable primary sarcomas showed a clear-cut resistance against the isografting of established specifically antigenic Rous tumors. Transplantation tests performed on primary tumor hosts after extirpation of the tumors revealed neither any clear-cut immunity nor tolerance to the specific transplantation antigen(s). Serial pretreatment of operated primary tumor animals with irradiated autologous or syngeneic tumor cells resulted in a clear-cut transplantation immunity. Virus-neutralizing activity was only found in a few sera from newborn infected mice, and in these cases there was no positive correlation with the transplantation immunity. It seems probable that a successful immunization against the RSV-SR specific transplantation antigen(s) prevents the development of primary tumors. There is no indication of any tolerance to this antigen in connection with the induction of primary tumors.
Insights
Newborn mice infected with Rous sarcoma virus (RSV-SR) showed resistance to tumor grafts if they didn't develop primary tumors. Immunization against tumor antigens may prevent Rous sarcoma virus development.
Area of Science:
- Immunology
- Virology
- Oncology
Background:
- Rous sarcoma virus (RSV-SR) is an oncogenic retrovirus.
- Understanding the host immune response to RSV-SR is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate transplantation immunity and virus-neutralizing antibodies in mice inoculated with RSV-SR.
- To determine the role of specific tumor antigens in the immune response to RSV-SR.
Main Methods:
- Mice were inoculated with RSV-SR at birth.
- Transplantation tests were performed using Rous tumors.
- Virus-neutralizing antibody levels were assessed.
- Mice were pretreated with irradiated tumor cells.
Main Results:
- Mice without primary tumors exhibited resistance to tumor isografts.
- Primary tumor hosts, post-excision, showed no clear immunity or tolerance to tumor antigens.
- Serial pretreatment with irradiated tumor cells induced transplantation immunity.
- Virus-neutralizing antibodies were detected in few sera, with no correlation to transplantation immunity.
Conclusions:
- Successful immunization against RSV-SR specific transplantation antigens likely prevents primary tumor development.
- No evidence of tolerance to tumor antigens was observed during primary tumor induction.